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ABSTRACT 
 
Clinical prediction scores such as the modified Wells score have proved useful to determine 
the likelihood for the presence of lower limb deep venous thrombosis (DVT).  Infection with 
HIV may affect the validity of this approach in the South African context.  This study of 230, 
mostly inpatients, of which 40% were HIV positive, confirms the validity of the modified 
Wells score in a South African population with a high HIV seroprevalence.  The score was 
found to be most accurate when performed within 48 hours of initiation of anticoagulation 
therapy and when combined with D-dimer assay result.  The more widespread utilisation of 
this score, especially in conjunction with the D-dimer assay as part of a diagnostic algorithm 
will make investigation of DVT simpler and more cost effective.  A diagnostic algorithm 
previously proven to be cost effective is suggested for adoption in local clinical practice as 
well as a basis for future research. 
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1 INTRODUCTION  
1.1 BACKGROUND  
Deep venous thrombosis (DVT) of the lower limbs is a common condition which affects a 
significant proportion of the South African population each year.1   Prompt and accurate 
diagnosis of DVT is important to avoid the potentially fatal complication of embolization to 
the pulmonary arterial circulation.2   Signs and symptoms of DVT, such as leg pain and 
swelling, are non-specific, occurring also in other conditions such as congestive cardiac 
failure, cellulitis and chronic venous insufficiency. This makes it difficult to diagnose DVT 
based on clinical signs and symptoms alone. 
Prediction scores based on clinical findings have proved useful to determine the likelihood 
for the presence of DVT.1   Several such scores exist but the Wells score is the oldest and 
most widely known of these.3   The Wells score, unlike other prediction scores, does not rely 
on the results of special investigations such as arterial blood gases, chest x-ray or 
electrocardiograph.  The Wells score initially designed stratified patients into 3 groups (high, 
intermediate and low risk).1   More recent work by Wells has simplified the test into a 
dichotomised version indicating whether DVT is likely versus unlikely.1  This modified version 
was the one used in this study and will be referred to as the ‘modified Wells Score’. 
 
 
Raised levels of D-dimer in the blood may indicate the presence of a deep vein thrombosis.  
The D-dimer is a product produced in the blood during fibrinolysis.  The levels of D-dimers in 
the blood rise in the presence of an intravascular thrombus, e.g. DVT.  Raised levels are, 
however, nonspecific in making the diagnosis of DVT and may be present in pregnancy, liver 
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disease, malignant conditions and systemic inflammatory conditions.5   The D-dimer assay is 
thus sensitive but not specific for the presence of a DVT.  The major clinical utility of the D-
dimer is that due to a high negative predictive value, a negative test is considered to 
effectively exclude the presence of a DVT in non-pregnant outpatients with no co-morbid 
illnesses.7   
 
In several studies validating the Wells score, a combined approach of using Wells scoring 
and D-dimer assay was found to be even more accurate in the exclusion of the condition in 
low-risk patients.3, 6, 8, 9   It has been shown that this approach is cost effective as a 
significant number of patients do not need to be referred for a confirmatory venous Doppler 
ultrasound (VDU).1 
 
Due to the limited resources available in the public health care sector, it is important that 
the viability of adopting such cost and labour saving strategies be investigated for the South 
African context.  There are, moreover, other unique differences between the local setting 
and the situation in which previous studies validating the combined Wells score and D-
dimer were carried out.  Medical professionals in South Africa work in a high human 
immunodeficiency virus (HIV) seroprevalence setting.  The relationship between HIV and 
vascular disorders such as DVT is complex but HIV has been established to increase the risk 
of DVT as well as influencing the results of the D-dimer test.4, 10   HIV patients have 
generalised suppression of their immune systems as well as a reduced ability to mount an 
inflammatory response.  Although this has not been specifically studied previously, the 
clinical presentation of DVT in HIV positive may differ from that in HIV negative patients.  
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This in turn may affect the accuracy of clinical prediction scores such as the Wells score in 
the local setting. 
 
The study reported on here sought to investigate the validity of the modified Wells Score in 
combination with the D-dimer assay in predicting the risk for deep vein thrombosis in a local 
population of patients referred for VDU.   The study is unique due to the high proportion of 
HIV positive patients included.  It included both inpatients and outpatients and relied on the 
referring doctor to assess the patient’s modified Wells score which accurately reflects how 
these tests would be applied in clinical practice. 
 
1.2 STUDY OBJECTIVES 
1. To determine the diagnostic performance of the modified Wells Score and D-dimer 
assay in a patient sample from three public hospitals in Johannesburg (Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH), Chris Hani Baragwanath Hospital 
(CHBH) and Helen Joseph Hospital (HJH)) 
2. To investigate any  effect of HIV positivity on the accuracy of these tests 
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2 LITERATURE REVIEW  
2.1 INTRODUCTION 
In this chapter, the latest literature regarding deep vein thrombosis, clinical prediction 
scores in general and the Wells score in particular are reviewed, the D-dimer assay, the 
relationship of HIV to deep venous thrombosis and strategies, particularly their cost 
effectiveness, in the investigation of suspected deep venous thrombosis are also discussed. 
 
2.2 DEEP VENOUS THROMBOSIS 
Deep venous thrombosis is a common condition with clinically significant DVT occurring in 
about 100 per 100,000 people annually.11    Although no specific epidemiological data is 
available from South Africa, DVT is a commonly encountered health problem in local 
hospital practise. 
 
The pathophysiology of deep venous thrombosis has been related to the ‘Virchow triad’ of 
abnormal venous blood flow, usually due to stasis, vessel wall abnormality or damage, and 
abnormalities in the blood constituents such as platelets and the factors involved in the 
coagulation and fibrinolytic pathways resulting in a predisposition to develop a DVT or 
venous thromboembolism (VTE).12   Causes of venous stasis include prolonged bed rest or 
immobilisation of the limbs, e.g. casts for fracture treatment.  Hypercoagulable states are 
found in patients who have risk factors including recent major surgery or trauma, 
pregnancy, liver disease, nephrotic syndrome and active cancer, as well as certain drugs 
such as oral contraceptives.11, 13, 14    Institutionalised patients i.e. hospitalised patients or 
patients resident in nursing homes are also at increased risk of DVT.15 
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Common symptoms of DVT include limb pain and swelling.  Physical examination may show 
unilateral oedema, warmth, and dilation of superficial veins.  All these features are non-
specific and may occur in cellulitis, ruptured Bakers cyst, muscular injury, Achilles tendonitis 
or rupture.1, 16 
 
The most dangerous complication of DVT is  embolization into the pulmonary arterial 
system with resultant increased pulmonary arterial vascular resistance mainly due to 
hypoxic vasoconstriction which may result in right heart failure.  Additional 
pathophysiological sequelae are increased total alveolar dead-space as well as ventilation 
perfusion mismatches.2   The mortality rate for clinically significant pulmonary embolism 
varies according to the size of the embolism or ‘clot burden’.   For massive pulmonary 
embolism the mortality rate is between 30-60% in the acute setting.17   Non-massive 
pulmonary embolism has a lower mortality rate however these patients are at risk of 
recurrent thromboembolism if the risk factors for the initial thromboembolic event 
persist.18, 19 
 
Initial therapy for deep venous thrombosis usually involves either unfractionated heparin or 
low molecular weight heparin (LMWH) such as enoxaparin sodium.  The ease of 
administration and efficacy of LMW heparin has made this the preferred anticoagulant for 
the treatment of DVT.20   LMWH can be administered subcutaneously, has a longer biologic 
half-life, dosing is fixed, laboratory monitoring is not required and some adverse effects of 
unfractionated heparin, such as thrombocytopenia, are less likely.21, 22 
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Whilst the prompt initiation of anticoagulation therapy with heparin is important to reduce 
risk of clot propagation and  embolization, such therapy has potentially severe adverse such 
as haemorrhage and thrombocytopenia. Approximately 2% of patients experience major 
bleeding within the first 3 months of therapy.23   The estimated fatality rate for each episode 
of major bleeding is 13%.23  Prolonged heparin therapies also places patients at risk of 
heparin-induced thrombocytopenia (HIT).22   Because of these complications associated with 
anticoagulation therapy, prompt and accurate diagnosis of DVT is important in clinical 
practise to limit the need for commencement of treatment for suspected DVT until its 
presence can be ruled out. 
 
2.3 D-DIMER 
D-dimer is a fibrin degradation product which is produced as a result of fibrinolysis of a 
thrombus.  It consists of two covalently cross-linked D-regions of adjacent fibrin monomers 
that cannot be further lysed by the fibrinolytic enzyme plasmin.   
 
Blood assay for D-dimer levels is a commonly used diagnostic test which has a high 
sensitivity for deep vein thrombosis but lacks specificity since elevated levels may also be 
the result of other conditions such as pregnancy, liver disease, malignancy and inflammatory 
conditions (including chronic HIV infection).4 The major current clinical usage of this test is 
in screening patients for the presence of thrombotic conditions, mainly deep venous 
thrombosis and pulmonary embolism.  The D-dimer assay has been shown to have a high 
negative predictive value in the evaluation of patients with suspected DVT.7   A review by 
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Stein concluded that: “For excluding PE or DVT, a negative result on quantitative rapid ELISA 
is as diagnostically useful as a normal lung scan or negative duplex ultrasonography 
finding”.24   
 
There are many types of D-dimer assay, both quantative and semi-quantative.  These fall 
into three main types: enzyme-linked immunosorbent assay (ELISA), latex agglutination 
assays and whole-blood agglutination.5  The performance of the D-dimer test varies 
depending on the type of test.24, 25  Different tests vary in terms of different sizes of fibrin 
degradation products that can be detected, the anti-D-dimer monoclonal antibodies from 
different assays recognize different epitopes, and discrepancies can exist in the assay 
format, calibration standards, and instrumentation.5 Assays may be defined as high or 
medium sensitivity8 and there is no standardisation as to the cut-off values for a positive 
test.  Test-specific cut off values are thus used. The sensitivity of D-dimer tests considered to 
have good analytical performance is above 95% and specificity above 40%.26  In a recent 
review examining performance of various D-dimer assays in current use,5 the following 
findings were presented: ELISA and enzyme-linked fluorescence assay (ELFA), the microplate 
ELISA and the automated quantitative turbidimetric assays (such as the INNOVANCE, STA-
LIATEST D-DI and D-DIMER PLUS assays utilised in this study) have a higher sensitivity than 
the whole-blood agglutination assay (95% compared with 85%), but a lower specificity (50% 
vs 70%).  The major advantage of the whole-blood agglutination assay is that it is a 
qualitative test which is readily available and fast to perform and thus is the test commonly 
used in the emergency department setting.  
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The local laboratories of the three hospitals which provided data for this study use three 
different types of latex-agglutination tests for D-dimer assays from different manufacturers.  
Thus CMJAH laboratory uses the STA-LIATEST D-DI D-dimer test manufactured by Stago, 
CHBH uses D-DIMER PLUS manufactured by Siemens and HJH laboratory uses the 
INNOVANCE D-dimer assay manufactured by Siemens.  These are all latex agglutination 
immunoturbidimetric assays with high sensitivity.  They are the most commonly used D-
dimer assays produced commercially for use in clinical practice as they can be done rapidly 
and are sensitive. ELISA tests are the gold standard type of test but are not easy to use in 
practice as they are time consuming, require batching, which is expensive, and are more 
suitable for research applications.  However, latex agglutination assays, such as the 
immunoturbidimetric assay, have been shown to have equivalent diagnostic performance to 
D-dimer ELISA tests.27 
2.4 WELLS CLINICAL PREDICTION SCORE 
Individual clinical signs and symptoms are of limited value in the diagnosis of DVT.  Results 
of a large meta-analysis 1 showed that the likelihood ratio for most individual signs and 
symptoms of DVT is close to 1 (see Table 1): 
Table 1 Likelihood ratios of various clinical signs and symptoms of deep venous thrombosis (in meta-analysis by 
Goodacre, 2006) 
CLINICAL FEATURE NUMBER OF STUDIES Likelihood ratio (LR) (95% 
confidence interval (CI)) 
Calf pain 12 1.08 (0.96 – 1.20) 
Calf swelling 13 1.34 (1.14 – 1.53) 
Past history of DVT 9 2.54 (1.79 – 3.61) 
Malignancy 17 2.61 (2.03 – 3.36) 
Recent immobilisation 14 1.93 (1.63 – 2.28) 
Recent surgery 14 1.72 (1.35 – 2.19) 
Obesity 4 1.02 (0.75 – 1.38) 
Difference in calf diameter 7 1.76 (1.43 – 2.18) 
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Homan’s sign 11 1.40 (1.18 – 1.66) 
Warmth 11 1.31 (1.08 – 1.60) 
Tenderness 12 1.18 (1.06 – 1.32) 
Erythema 6 1.30 (1.02 – 1.67) 
Oedema 10 1.18 (0.99 – 1.41) 
Modified from Goodacre, 2006 
  
The study concluded that, if taken individually, only malignancy and a past history of DVT 
were useful in ruling in the diagnosis of DVT.   
 
Thus, because of nonspecific clinical symptoms and signs and the major implications of 
missing the diagnosis of DVT, objective clinical prediction scores have been developed to 
assist clinicians in determining the clinical probability of DVT.   
 
The Wells score is one of the oldest and most commonly used objective clinical prediction 
scores for the presence of DVT.8  The Hamilton score is a recently devised six item score 
whose performance in a single study compared favourably with the Wells score.28   This test 
has not been nearly as extensively evaluated as the Wells score.   Other scores relying on 
clinical variables only are the Kahn score, a four item score, and the St Andre score which is 
a six item score.29, 30  In the limited number of studies conducted using these scores, 
performance of the Kahn score and St Andre score performance proved inferior to the Wells 
score.29  Other scores, namely the Geneva score and the Prospective Investigative Study of 
Acute Pulmonary Embolism Diagnosis (PISA-PED) score exist.31  These, however, include 
results of special investigations such as arterial blood gas in the former and chest x-ray in 
the latter.   
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The Wells score is based on only traditional risk factors such as recent surgery and 
malignancy as well as findings on clinical examination (see Table 2).   
 
 
Table 2 Modified Wells score.  The modified Wells score is a score out of 9 based on risk factors such as recent surgery 
and malignancy as well as findings on clinical examination. 
MODIFIED WELLS SCORE5  
RISK FACTOR   POINTS 
Active cancer (patient receiving treatment for cancer within the 
previous 6 months or currently receiving palliative treatment)  
1 
Paralysis, paresis, or recent plaster immobilization of the lower 
extremities 
1 
Recently bedridden for 3 days or more, or major surgery within the 
previous 12 weeks requiring general or regional anaesthesia  
1 
Localized tenderness along the distribution of the deep venous system  1 
Entire leg swollen  1 
Calf swelling at least 3 cm larger than that on the asymptomatic side 
(measured 10 cm below tibial tuberosity) 
1 
Pitting oedema confined to the symptomatic leg  1 
Collateral superficial veins (non-varicose)  1 
Previously documented deep-vein thrombosis  1 
Alternative diagnosis at least as likely as DVT -2 
 Score > or = 2 DVT likely; 
score < 2 DVT unlikely 
 
 
As individual clinical features of DVT have been found to have a low positive predictive value 
of about 15% and since no single clinical risk factor or finding of clinical examination is 
sufficiently sensitive and specific for deep venous thrombosis,32 the combination of these 
into a prediction score has proven to be useful in clinical practice.  The score initially 
designed stratified patients into 3 groups as follows (see Table 3): 
11 
 
 
Table 3 Original Wells score stratification.  The score stratified patients into 3 groups. 
SCORE RISK GROUP 
<0 Low  
1-2 Intermediate  
>2 High  
 
More recent work by Wells has simplified the test into a dichotomised version indicating 
whether DVT is likely versus unlikely6 (see Table 4).  The dichotomised version of the Wells 
score  was used in this study and will be referred to as the ‘modified Wells Score”: 
 
Table 4 Modified Wells score stratification.  The modified score was simplified and stratified patients into 2 groups. 
SCORE RISK GROUP 
<2 Low clinical probability 
>=2 High clinical probability 
 
 
This has effectively raised the cut-off of a significant Wells score result, increasing the 
specificity while decreasing the sensitivity.  This was found to be advantageous and safe as 
long as the test was used together with a D-dimer assay.6   Other stratification methods 
have been used for example , combining the high and intermediate probability groups.33 
 
The Wells score has been extensively validated in outpatient centres for patients with low 
clinical probability of DVT in hospitals in Canada, Europe and the United states.8, 34  The 
studies carried out during the development and subsequent validation of the test were 
conducted mainly on outpatients. However two studies conducted on hospitalised patients 
12 
 
showed that the Wells score was accurate in these populations also.3, 30  Pregnant women 
were not included in the majority of these studies. 
 
The value of an objective prediction score has been questioned.  In the PIOPED study,35 
physicians used clinical judgment alone to categorize their clinical suspicion of pulmonary 
embolism (PE) as high, intermediate, or low and some studies have found that doctors 
subjective assessment of DVT risk is comparable to the performance of objective clinical 
prediction rules.36  However, in this study, the assessing physicians were more experienced 
with the clinical evaluation of DVT than is generally the case in the local setting, where the 
evaluation of the patient is often the responsibility of interns or junior medical officers, 
especially in the initial emergency setting.  Although no studies assessing the differences in 
accuracy of clinical assessment for DVT could be found, it is possible that the accuracy of 
junior doctor’s clinical evaluation may be inferior to that of the doctors participating in the 
abovementioned study and may be assisted by the use of an objective measure such as the 
Wells score.  
 
2.5 VENOUS DOPPLER ULTRASOUND 
VDU is the most widely utilised test in the investigation of patients with suspected DVT.  This 
is mainly because conventional venography is painful, invasive and utilises potentially 
harmful iodinated contrast material. Venography may induce DVTs in up to 2% of patients.37  
Venography is also not technically possible in 10% of patients due to difficulties in vein 
cannulation related to obesity or excessive swelling.31 
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VDU has several limitations.  VDU is generally dependent on the operator’s skill and 
experience.  VDU cannot reliably distinguish between acute and chronic thrombus (which 
does not need treatment).  It is important to define the terms “proximal” and “distal DVT”.  
“Proximal” DVT generally refers to thrombus occurring in the popliteal vein or femoral veins 
whereas “distal DVT” refers to thrombus occurring in the calf veins.   
 
Sensitivity is reduced for thrombi in the pelvic and calf veins and in the presence of 
extensive subcutaneous oedema or obesity.  However, a sensitivity and specificity of up to 
96% and 97% respectively for proximal DVT on meta-analysis compared with venography 
have made VDU the imaging of choice for venous thrombosis.1, 38  VDU is somewhat less 
sensitive for DVT that is isolated to calf veins with sensitivities of 41 – 75% reported, 
depending on the techniques used.1  In current practice, VDU is considered the most useful 
widely available test and the decision to treat the patient relies on the result of the VDU.     
 
Performance of a VDU is not standardised.  Several manoeuvres such as adequacy of venous 
compression, phasicity of Doppler waveform and response to augmentation manoeuvres, 
such as manual distal calf compression, may be utilised as evidence for or against the 
presence of venous thrombus.  Practice also varies in terms of the examination of calf veins 
because the presence of an isolated calf vein thrombus has only a very low risk for 
pulmonary embolism.  A calf vein thrombus may, however, progress distally into the larger 
veins of the thigh, and thus most authorities recommend follow-up VDU to detect clot 
propagation and to ascertain any need for treatment.  Many practitioners in the local 
setting do not routinely evaluate the calf veins. 
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Emergency venous Doppler to exclude deep venous thrombosis is not widely available due 
to resource constraints and the prioritisation of other imaging studies and more emergent 
conditions after hours.  These resource constraints refer primarily to staff availability and 
equipment availability after hours.  Usually only 1 or 2 registrars are on duty at any specific 
time and the ultrasound equipment available after hours is often of low technical quality 
particularly pertaining to the Doppler capabilities of the machine.  VDU are often delayed 
for 48 hours or even longer after presentation.  Current practice is to initiate anticoagulation 
therapy in those with a reasonably high clinical suspicion of DVT while waiting for a VDU to 
be performed.  For outpatients this usually means admission to hospital to await the VDU.   
 
2.6 OTHER MODALITIES 
Several other modalities are currently available in the investigation of DVT.  These include 
plethysmography, computed tomographic (CT) venography and magnetic resonance (MR) 
venography.  These modalities have been shown to be useful but are either not widely 
accessible (as in the case of plethysmography), are expensive (as in the case of MRI) or 
involve ionising radiation (as in the case of CT).  For these reasons, in most institutions, 
these modalities are only utilised if the findings of the VDU are equivocal.  They are not 
widely utilised in the local setting of this study and thus will not be discussed further. 
 
2.7 COMBINED APPROACH 
In a large study,6 combining the modified Wells score with D-dimer assay resulted in a 
negative predictive value of 99.1% for the presence of DVT.  Using this approach, 218 of 562 
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patients with suspected DVT avoided unnecessary VDU.  The finding was confirmed in a 
comprehensive systematic review of 14 studies involving more than 8000 patients using the 
Wells clinical prediction rule, of which 11 of the studies looked at the combined Wells score 
and D-dimer approach.8  The overall prevalence of DVT in this meta-analysis was 19%.  The 
pooled sensitivity, specificity, and negative LRs of D-dimer testing in the low clinical 
probability group were 88%, 72%, and 0.18%.8  The LRs for a normal result on a high 
sensitive D-dimer assay among patients with low clinical suspicion were 0.10.8  The authors 
concluded that  diagnostic accuracy for DVT improves when the clinical probability is 
estimated before diagnostic tests are performed.8  Furthermore, the Wells score test in 
combination with D-dimer assay has the potential to identify patients for whom lower limb 
ultrasonography is unnecessary.8  This is based on results from the above meta-analysis 
which found that the combination of  a negative D-dimer result and a low or moderate 
clinical probability estimate created a probability estimate after testing for DVT of less than 
1%.8  This approach has also proved accurate and cost effective in specific patient 
populations such as cancer patients in a Canadian hospital.9  The viability of adopting such 
cost and labour saving strategies in the South African context should be investigated. 
 
2.8 COST EFFECTIVENESS AND THE USE OF STRUCTURED ALGORITHMS IN DVT 
INVESTIGATION 
The major advantage of structured investigative algorithms in medical practice is to improve 
care by advocating evidence-based, clinically effective practices to clinicians who may not be 
aware of the latest evidence.39, 40, 41  Further advantages include cost reduction, 
standardization of practice, and reduction of medical liability.40  The purpose of such 
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guidelines for clinical practice, according to Shiffman,39 “…are meant to provide a vehicle for 
facilitating consistent, effective, and efficient medical practice with the overall goal of 
improving health outcomes and reducing inappropriate care.” 
 
No clinical guidelines or standard algorithms related to the investigation of DVT are in 
widespread use in the Johannesburg hospitals.  Although no clinical audit of practice in the 
investigation of DVT has been published, many patients with suspected DVT are  sent for 
VDU.  This is because it is readily available, cheap and accurate first-line modality.  These 
patients may or may not have had a D-dimer blood test prior to VDU with the decision to 
obtain the test being at the discretion of the clinician. 
 
The combination of clinical probability scoring, D-dimer blood testing and VDU into 
diagnostic algorithms have been shown by several studies to be a highly cost effective 
strategy.1, 42, 43  A recent large meta-analysis investigating clinical and cost-effectiveness of 
all non-invasive tools used in the diagnosis of deep vein thrombosis examined multiple 
algorithms in use in hospitals throughout the United Kingdom (UK).1  As part of this study, a 
postal survey of UK hospitals was performed to determine current practice in the work-up 
of DVT.   The cost-effectiveness analysis determined the net benefit of using each algorithm 
in terms of the cost per quality-adjusted lifeyear (QALY).1  This study identified the 
diagnostic algorithm used by Wells in his 2003 study as being the most cost effective 
algorithm which utilised modalities widely available in the United Kingdom’s National Health 
Service (NHS) (Well scoring, D-dimer and above leg VDU) (Figure 1): 
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Figure 1  The diagnostic algorithm used by Wells in his 2003 study.  This was the most cost effective algorithm which 
utilised modalities widely available in the United Kingdom’s National Health Service (NHS) 
 
 
This algorithm compared favourably with costs incurred when a strategy of routine VDU for 
all patients with suspected DVT is followed1 as summarised below (see Table 5): 
Table 5  Costs incurred per 1000 patients for algorithm of ultrasound for all DVTs compared to selected ultrasound 
according to the Wells algorithm 
 Cost of investigations 
(£) / 1000 patients 
Cost of treatment and 
complications of non-
treatment (£) / 1000 
patients 
Total cost (£) / 1000 
patients 
VDU for all 59 364 196 536 255 900 
Selected VDU & 
Wells Algorithm 
47 527 168 556 216 082 
 
This analysis concluded that, for the same health benefit, up to £39 818 (equivalent to R445 
962 at the time of writing) could be saved per 1000 patients.  While the report commented 
Wells score 
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that the use of repeat VDU scanning in patients with an initially negative VDU did identify 
additional patients with false negative VDU , it was more expensive and thus the 
incorporation of repeat VDU scanning would depend on the amount available for the 
additional health benefit.1 
 
Although the cost-effectiveness data can by no means be directly applied to the local 
situation, in general terms it is likely that the relative costs of the various modalities and 
algorithms tested in the abovementioned cost-effectiveness analysis are probably similar in 
this country.  More specifically, availability of diagnostic tests and the most commonly 
utilised tests (i.e. VDU and D-dimer assay) appear to be the same as those utilised most 
commonly in this country.  Precise data on practise patterns and cost effectiveness for our 
setting will only be available once a similar cost effectiveness analysis has been performed 
by our Department of Health. 
 
The study reported here sought to determine whether the modified Wells score is valid in 
the local setting.   Potential benefits of such a study include validation of the modified Wells 
score in a local setting as well as assistance in designing cost-effective protocols for 
appropriate investigation of suspected DVT in this setting.   
 
2.9 EFFECTS OF HIV 
To date the Wells score has not been validated in the South African setting which differs 
from settings where previous studies have been conducted in terms of being characterised 
19 
 
by a high HIV seroprevalence.  The overall prevalence of HIV in the general population in 
South Africa is estimated to be 17.8% and in Gauteng 16.6%.44   
 
There appears to be no studies validating the Wells score in such a high HIV seroprevalence 
setting nor do any previous studies record data on the HIV status of the participants.  It is 
possible that factors such as high HIV seroprevalence may affect the validity of this test 
locally.  This effect may be significant as HIV seroprevalence in hospitalised patients is 
expected to be substantially higher than the general population.45, 46  
 
Infection with the human immunodeficiency virus has been shown to increase the risk for 
lower limb DVT via a number of mechanisms as recently reviewed by Eyal and Veller.47  
These include lower levels of natural blood anticoagulants such as Protein S48, Protein C49, 
and Heparin co-factor II50, higher levels of procoagulant factors such as von Willebrand’s 
factor and endothelial cell dysfunction due to direct infection with HIV.  In the limited 
number of studies done overseas to quantify the additional risk, the incidence of DVT in HIV 
infected individuals was found to be highly variable, between 0.19% and 18%.51  This is still 
substantially higher than the general population which has an annual incidence of 
approximately 0.05%.52  Despite this, previous large investigations of the epidemiology of 
and risk factors for DVT in other settings do not include a study of the role of HIV because 
the numbers of HIV patients in the institutions publishing these papers is small.11, 13  
 
In HIV, DVT risk may increase with lower CD4 counts53 and certain opportunistic infections 
such as cytomegalovirus (CMV) and tuberculosis (TB).54  There is also evidence for a possible 
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additional risk in patients on treatment regimens including protease inhibitors and 
rifampicin.55  In a high HIV seroprevalence setting the incidence of HIV-related DVTs is 
expected to be high.   In a recent publication presenting data from Charlotte Maxeke 
Johannesburg Academic Hospital, 11 out of 13 (84%) of patients with DVTs were HIV 
infected.56   
 
HIV patients are known to have reduced immune responses mainly due to CD4+ T-cell 
depletion as well as dysregulation of the immune system.57  The presentation of other 
conditions such as meningitis58 and pulmonary tuberculosis59 is known to be atypical in HIV 
positive patients in whom these conditions may be more chronic or indolent than in 
immunocompetent patients.  No studies have been done comparing the clinical 
presentation of HIV-associated DVT with DVT in HIV negative patients.  HIV may result in a 
reduced sensitivity of the Wells score as it partly relies on clinical examination findings of 
inflammation such as the degree and extent of leg swelling.    
 
HIV infection may also affect the accuracy of the D-dimer assay.  HIV is also known to result 
in systemic endothelial dysfunction.  This has been shown to be associated with increased 
levels of traditional markers of systemic inflammation including the D-dimer levels.4 In this 
context, the D-dimer level has actually been proposed as an independent marker of 
increased risk of adverse cardiovascular events in HIV positive patients.10  Because of these 
factors, the D-dimer test may have reduced positive predictive value in this group of 
patients.  This is unlikely to influence the negative predictive value of the test. 
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2.10 SUMMARY 
Clinical prediction scores such as the Wells score have proved useful to determine the 
likelihood for the presence of lower limb deep venous thrombosis (DVT).  In several previous 
studies validating the Wells score, conducted in developed countries such as Canada, France 
and the United States, a combined approach using Wells scoring and D-dimer assay were 
found to reliably exclude DVT in low-risk patients.  This study was undertaken in part 
because it is possible that infection with HIV may affect the validity of this approach in the 
South African context.  No clinical guidelines or standard algorithms related to the 
investigation of DVT are in widespread use in the Johannesburg hospitals.  The combination 
of clinical probability scoring, D-dimer blood testing and VDU in diagnostic algorithms have 
been shown by several studies to be a highly cost effective strategy.  The viability of 
adopting such cost and labour saving strategies in the South African context should be 
investigated.  The study reported here sought to determine whether the modified Wells 
score is valid in the local setting.   Potential benefits of such a study include validation of the 
modified Wells score in a local setting as well as assisting in designing cost-effective 
protocols for appropriate investigation of suspected DVT in this setting.   
 
  
22 
 
3 MATERIALS AND METHODS 
 
3.1 STUDY POPULATION 
The study reported on here was a prospective study of a combined sample of inpatients and 
outpatients with clinical signs and symptoms of lower limb deep vein thrombosis who were 
referred for VDU. Data collection commenced on 2/6/2010 and concluded on 27/10/2010. 
The study was performed in three of the hospitals served by the University of the 
Witwatersrand Radiology Department: Chris Hani Baragwanath Hospital Helen Joseph 
Hospital and Charlotte Maxeke Johannesburg Academic Hospital.  
 
 
All non-pregnant patients 18yrs or older were eligible for inclusion.  The study sample was 
limited to a convenience sample (a sample where the patients are selected at the 
convenience of the researcher).  This is because there was limited access to patients mainly 
because participation was contingent on the agreement of both referring clinicians and 
patient. 
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3.2 SAMPLE SIZE 
The prevalence of DVT in patients referred for venous Doppler was estimated to be 35%.  A 
sensitivity of 95% and confidence limits of 5% were required so a minimum sample size of 
209 was aimed for.  This was calculated according to the following formula for sample size 
estimation for a required sensitivity:60 
 
 
Desired sensitivity (SN) = 95% 
Confidence interval (W) = 5% 
 Expected Prevalence (P) = 35%  
 z is a constant = 1.96 
                
  N = (z2 x (SN(1-SN))/W2/P)  
                   = 209 patients    
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3.3 MEASUREMENTS TOOLS 
Three major measurement tools were used: a data collection form, D-dimer assay and a 
VDU.   
3.3.1 Data Collection Form 
A brief form regarding each patient whose data was included was completed by the 
referring clinician (see Appendix 2).  The information recorded included the following: 
- Patient demographic data:  
o name  
o age  
o hospital number 
o referring doctor and referring doctors telephone number;  
 
- Clinical data: 
o D-dimer assay result (if available) 
o HIV status (if known) and whether the patient was on antiretroviral 
medication 
o Pregnancy status 
o Whether patients had been on therapeutic anticoagulation therapy for 
longer than 48hours before ultrasound  
o Information required to calculate the modified Wells score.   
- VDU result 
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3.3.2 D-dimer 
Each patient had the results of their D-dimer assay recorded, if available.  The relevant local 
laboratories of the three hospitals which formed the sites for the study used three different 
D-dimer assays as indicated in the table below: 
 
Table 6 The D-dimer assays in use in the relevant local laboratories of the three hospitals 
HOSPITAL TEST 
CMJAH STA-LIATEST D-DI (Stago) 
CHBH D-DIMER PLUS (Siemens) 
HJH INNOVANCE (Siemens) 
 
The above are latex agglutination immunoturbidimetric assays.  Immunoturbidimetric 
assays have been shown to have equivalent diagnostic performance to D-dimer ELISA 
tests.27 A positive assay is defined as greater than 500 μg per litre for the INNOVANCE and 
STA-LIATEST D-DI tests and greater than 250 μg per litre for the D-DIMER PLUS (information 
obtained from respective test package inserts).  For standardisation purposes, in the 
relevant laboratories, the result is divided by a factor of 2.  Thus in this study, the result is 
considered positive if the D-dimer value is greater than 250 μg per litre for patients from 
any of the three hospitals (Elise Schapkaitz, Consultant Haematologist, personal 
communication).   
 
3.3.3 Venous Doppler 
For each patient a VDU was performed by a sonographer, radiology registrar or radiology 
consultant.  The vein segments routinely examined extend from the common femoral vein 
to the popliteal vein with examination of the calf veins performed by some operators but 
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not others.  Protocol for performance of the tests was not standardised but all of the 
ultrasound machines used could perform pulsed wave Doppler as well as colour Doppler. 
 
3.4 DATA COLLECTION  
In order to facilitate data collection, the heads of the departments of Medicine, Surgery and 
Emergency Medicine were informed of the study prior to its commencement via email and 
their co-operation was requested (see Appendix 3).  These departments are responsible for 
the majority of requests for VDU.   A brief presentation to inform the radiology department 
of the study took place during a regular case presentation meeting.  Specifically, Ms Z 
Holland (CMJAH) and Dr A Bera (CHBH), who are responsible for ultrasound in their 
respective hospitals, as well as the registrars doing their ultrasound blocks in the three 
hospitals, were approached for their co-operation. 
 
The data collection process was conducted in two ways.  In the first instance, the data 
collection form together with the consent form was made available in the respective 
ultrasound departments, with copies being distributed in advance to all clinicians who 
showed a willingness to participate.   
 
When booking the VDU, clinicians were informed about the study and encouraged to 
participate.  If they agreed, they were supplied with the data collection form and consent 
form.  The data collection form and consent form were completed before booking the 
patient, the completed forms being stapled to the radiological request form.   Once the 
patient came for the venous Doppler study, the data collection form was detached and the 
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radiologist or sonographer indicated on the form whether the test was positive or negative.  
The form was then placed in a designated collection box.   In order to maintain 
confidentiality, the section of the form with the patients name and other identifying data 
was separated from the section with the patient’s blood results, clinical findings and 
ultrasound result.  The forms were linked by a numerical code known only to the researcher.  
Supplies of the forms were replenished on a weekly basis.    
 
In addition, as far as was logistically possible, the statistics books for ultrasound were 
examined on a daily basis to find inpatients that had been missed by the first process.  These 
patients were found in the wards and their data added to the study provided they met the 
inclusion criteria and gave informed consent.  The modified Wells score and clinical 
information was recorded by staff from the radiology department.  In all cases, recruited 
patients signed an informed consent form (see Appendix 1).   
 
The study was an open study and the operator performing the VDU study was not blinded 
to the Well’s score or the D-dimer result.  
 
In order to assure the quality of the data, every few days the data collection forms were 
checked for completeness and any missing or unclear data was, as far as possible, clarified 
with the referring doctor.  All outstanding D-dimer results were followed up with the 
respective laboratories, using the patients’ hospital numbers as recorded on the forms.   In 
cases where data could not be completed, forms had to be discarded. 
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The study concluded when a sufficient amount of data had been obtained.  As mentioned 
above, this was estimated to be at least 209 patients.  The final number included was 230.  
Ideally the sample size would have been larger in order identify if small differences between 
subgroups were statistically significant.  However, the study had to be terminated due to 
time constraints. 
 
3.5 DATA ANALYSIS 
Data was entered on a spreadsheet and basic descriptive statistical analysis was performed 
using Microsoft Excel (see Appendix).   The online calculator OpenEpi (Dean AG, Sullivan KM, 
Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. 
http://www.openepi.com)61  was used to calculate the measures of test diagnostic 
performance including the ROC curves for the modified Wells score and D-dimer tests and 
the likelihood ratios for components of the modified Wells score and HIV positivity.  The t-
test was used to compare the age of the group of patient with DVT and the group without.  
The chi-squared test (two-tailed, Yates corrected) was used to compare the gender and 
outpatient or inpatient status of the group of patient with DVT and the group without as 
well as the DVT prevalence in HIV positive, negative and unknown groups.  The ANOVA test 
was used to compare the mean ages between HIV positive, negative and unknown groups.  
The agreement between the modified Wells score and the reference standard (VDU) was 
determined using the McNemar test and the Cohen Kappa test.   
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3.6 ETHICAL CONSIDERATIONS 
Although the study required recording of potentially sensitive information such as HIV 
status, the data was collected and stored in a confidential manner.  No HIV testing was 
performed, as the patient’s known status was recorded.  Blood was also not taken for D-
dimer estimation as the patients known result was recorded.   Thus, no additional invasive 
testing was undertaken.  VDU was performed as usual.  Overall, the study had a minimal 
impact on the normal workflow of the ultrasound departments.   
 
A brief information sheet explaining the study was provided to the participants (see 
Appendix 1).  Informed consent was obtained in all cases before the patients were enrolled 
in the study.  Although the study subjects were not expected to benefit directly from 
participation in the study, results were expected to make a positive contribution to medical 
knowledge regarding deep venous thrombosis in the local setting and may make the 
investigation process for patients presenting with this condition in the future more efficient.   
 
Approval for this study from the University of the Witwatersrand Ethics Committee was 
obtained and the ethical clearance certificate (M10213) was issued on 16/04/2010 (see 
Appendix 4). 
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3.7 SUMMARY 
The study reported here was a prospective study in a combined sample of inpatients and 
outpatients from three Johannesburg teaching hospitals in order to determine the 
diagnostic performance of the modified Wells score and D-dimer assay using VDU as a 
reference standard test.  Three major measurement tools were used: a data collection form, 
D-dimer assay and a VDU.  Basic descriptive statistical analysis was performed using Excel.   
The online calculator OpenEpi was used to calculate the measures of test diagnostic 
performance.  Approval for this study from the University of the Witwatersrand Ethics 
Committee was obtained.     
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4 RESULTS  
4.1 DEMOGRAPHICS 
A total of 230 patients were included in the study.  Six patients could not be included as they 
had not completed the consent form.  Five patients could not be included because they 
were pregnant.  Two patients could not be included because they were underage.  This left 
230 patients for analysis.  The mean age of included patients was 44.8 (SD 16.0, range 18-
89); 107 (46.5%) were male and 123 (53.5%) were female.   
 
Patients were recruited from Chris Hani Baragwanath (113 patients, 49%), Charlotte Maxeke 
Johannesburg Academic Hospital (96 patients, 42%) and Helen Joseph Hospital (21 patients, 
9%).  The sample comprised 173 (75.3%) inpatients and 57 (24.8%) outpatients (see Figure 
2): 
 
 
Figure 2  Numbers of in- and outpatients from the three hospitals 
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Of the total, 96 patients (42.6%) had DVT and 134 (58.3%) did not.  Other characteristics of 
the study population are summarised below (see Table 7): 
 
Table 7 Summary of various characterstics of the study population 
 Total DVT Present DVT absent p 
Study 
population 
230  96 (41.7%) 134 (58.3%) n/a 
Mean age 
(SD) 
44.8 (16.0) 39.7 (12.5) 48.1 (17.8) 0.00005 
(t-test) 
Sex 
    Male 
    Female 
 
107 (46.5%) 
123 (43.5%) 
 
48  
48  
 
59  
75 
0.447 
(chi2) 
Outpatients 
Inpatients 
57 (24.8%) 
173 (75.3%) 
15 
81 
42  
92 
0.01 
(chi2) 
  
The age of the patients with DVT was significantly lower than the patients without DVT.  
Significantly more inpatients had DVT’s in comparison to outpatients.    
4.2 D-DIMER 
In total, 146 (63%) patients had D-dimer results recorded.  Of these 122 (84%) were positive 
and 24 (16%) were negative.  
 
 
4.3 HIV 
In total, the HIV results of 188 (81.7%) of the patients were recorded.  Of these 188, 92 
(49%) were positive, 96 (51%) were negative.  Of the HIV positive patients, 46 were on ARV’s 
and 46 were not on ARV’s.   30 of the 46  patients (65.2%) on ARV’s had DVT compared to 25 
of the 46 patients (54.3%) who were not on ARV’s.  There was not a statistically significant 
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association between the DVT rate between the patients on ARV’s and those not on ARV’s (p 
= 0.2985). 
 
Other demographic characteristics of the HIV positive and negative study groups are 
summarised below (Table 8): 
 
Table 8 Demographic characteristics of the HIV positive and negative groups 
 HIV positive HIV negative HIV unknown p 
Patients 92 (40.0%) 96 (41.7%) 42 (18.2%)  
Mean age (SD) 36.0 (11.6) 49.8 (16.0) 51.4 (17.8) 0.0012 
(ANOVA) 
Sex 
    Male 
    Female 
 
46 
46 
 
48 
48 
 
13 
29 
0.087 (chi2) 
Outpatients 
Inpatients 
13 
79 
25 
71 
19 
23 
0.00052 
(chi2) 
DVT 
  Present 
  Absent 
 
56  
36 
 
29 
57 
 
 
 
10 
32 
0.000024 
(chi2) 
 
Of note, statistically significantly more HIV positive patients had DVT’s in comparison to HIV 
negative patients.  The HIV positive group was also statistically significantly younger than 
the HIV negative patient group.  Statistically significantly more inpatients were HIV positive 
compared to negative and unknown groups. 
 
4.4 WELLS SCORE 
The most frequent modified Wells score items present were an alternative diagnosis 
(n=118), clinical examination findings such as calf swelling (n=121), pitting oedema (n=105), 
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entire leg swelling (n=94) and localised tenderness in the distribution of the deep venous 
system (n=74).  The most frequent item related to the clinical history was being bedridden 
for 3 days or more or recent surgery (n=51).  The frequency of all findings on the modified 
Wells score for all patients are summarised below (see Figure 3): 
 
 
 
Figure 3  Frequency of findings on the modified Wells score for all patients 
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Total values of the modified Wells score ranged from -2 out of 9 to 6 out of 9.  The 
mean score was 1.19 (SD 1.9).   The distribution of the modified Wells scores for all 
patients is summarised below (see Figure 4): 
 
 
 
Figure 4  Histogram of the distribution of the modified Wells scores for all patients (n=230) 
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4.5 EVALUATION IN ANTICOAGULATED PATIENTS 
Of the total of 230 patients, 184 (80%) were not on any anticoagulation treatment or had 
modified Wells score evaluation within 48 hours of initiation of anticoagulation and 46 
(20%) were evaluated more than 48 hours after initiation of anticoagulation (see Figures 5 & 
6). 
 
 
 
Figure 5  Summary of modified Wells score and Ultrasound findings in the group of patients not on anticoagulation 
treatment or evaluated within 48 hours of initiation of anticoagulation 
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Wells score  
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Figure 6 Summary of modified Wells score and Ultrasound findings in the group of patients evaluated after 48 hours of 
initiation of anticoagulation 
 
Performance of the modified Wells score as a diagnostic test in all patients (see Table 9) and 
the two subgroups (see Table 11 & 12) are summarised below.  Note that the terms “high 
clinical probability” and “low clinical probability” refer to the modified Wells score 
stratification.  The tables of results include likelihood ratios for the individual parameters of 
the modified Wells Score (see Table 10).  The overall performance of the modified Wells 
score in comparison to VDU was determined by means of a 2x2 table.  The level of 
agreement between the modified Wells score and VDU was determined with the McNemar 
test and the Cohen Kappa.  (See Table 12) 
 
Total pts 
230 
Evaluated after 48hrs 
46 
High probability Well 
score  
18 
DVT pos  
9  
DVT neg  
9 
Low probability Wells 
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 28 
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11  
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Table 9 Modified Wells score performance in all patients.  Note that the terms “High clinical probability” and “Low 
clinical probability” refer to the modified Wells score stratification.   
 DVT PRESENT DVT ABSENT TOTAL 
HIGH CLINICAL 
PROBABILITY 
64 32 96 
LOW CLINICAL 
PROBABILITY 
32 102 134 
 96 134 230 
 
      
      
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 66.67% (56.76, 75.29)   
Specificity 76.12% (68.24, 82.55)   
Positive Predictive Value 66.67% (56.76, 75.29)   
Negative Predictive Value 76.12% (68.24, 82.55)   
Diagnostic Accuracy 72.17% (66.05, 77.57)   
     
     
Table 10 Likelihood ratio for the Wells score parameters in all patients 
Modified Wells Score Parameters Likelihood Ratio 
for a positive 
finding 
95% CIs 
Alternative diagnosis 0.5886 (0.5214 - 0.6645) 
Cancer 0.4653  (0.0003255 - 665.1) 
Paralysis, paresis or recent plaster 
immobilisation 0.7614  
(0.004744 - 122.2) 
Bedridden for longer than 3 days 1.57  (1.202 - 2.051) 
Localised tenderness along deep venous 
system 2.736  
(2.434 - 3.075) 
Entire leg swollen 1.804  (1.669 - 1.95) 
Calf swelling >3cm compared to 
asymptomatic side 2.123  
(2.021 - 2.23) 
Pitting oedema confined to the 
symptomatic limb 2.179  
(2.046 - 2.321) 
Dilated collateral superficial veins 2.233  (0.1019 - 48.94) 
Previous documented DVT 2.513  (0.2068 - 30.52) 
 
The only parameters significantly associated with the presence of DVT were being 
bedridden for longer than 3 days, localised tenderness along deep venous system,  swelling 
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of the entire leg, calf swelling >3cm compared to asymptomatic side and pitting oedema 
confined to the symptomatic limb.   
 
The variables of cancer, paralysis, paresis or recent plaster immobilisation, dilated collateral 
superficial veins and a previous documented DVT did not have a statistical significant 
association with the presence of DVT.   
 
The presence of an alternative diagnosis equally likely than DVT was significantly negatively 
associated with the presence of DVT. 
 
The performance of the modified Wells score was significantly worse in the subgroup when 
the score was evaluated after 48 hours of anticoagulation therapy.  Because 
recommendations will be based on application of the score within 48 hours, further analyses 
excluded patients evaluated after this time. 
 
 
Table 11 Modified Wells score performance in patients evaluated after 48 hours of initiation of anticoagulation 
 DVT PRESENT DVT ABSENT TOTAL 
HIGH CLINICAL 
PROBABILITY 
9 9 18 
LOW CLINICAL 
PROBABILITY 
11 17 28 
 20 26 42 
 
      
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 45% (25.82, 65.79)   
Specificity 65.38% (46.22, 80.59)   
Positive Predictive Value 50% (29.03, 70.97)   
Negative Predictive Value 60.71% (42.41, 76.43)   
Diagnostic Accuracy 56.52% (42.25, 69.79)   
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  Table 12 Modified Wells score performance in patients on no anticoagulation treatment or evaluated within 48 hours of 
initiation of anticoagulation treatment 
 DVT PRESENT DVT ABSENT TOTAL 
HIGH CLINICAL 
PROBABILITY 
55 23 78 
LOW CLINICAL 
PROBABILITY 
20 86 106 
 75 109 184 
 
  
     
      
 
      
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 73.33% (62.37, 82.02) 
Specificity 78.9% (70.32, 85.51) 
Positive Predictive Value 70.51% (59.62, 79.48) 
Negative Predictive Value 81.13% (72.65, 87.44) 
Diagnostic Accuracy 76.63% (70.01, 82.16) 
Cohen's kappa (Unweighted) 
McNemar p-value                                  
0.5191 
0.6473 
(0.3747 - 0.6635) 
 
 
 
 
 
 
In patients on no anticoagulation treatment or evaluated within 48 hours of initiation of 
anticoagulation, there was moderate agreement between the modified Wells score and the 
VDU as determined by the Cohen Kappa test (as per Landis and Koch magnitude guidelines) 
and the McNemar test showed no significant difference between the tests. 
 
 
The prevalence of DVT in high clinical probability patients on no anticoagulation treatment 
or evaluated within 48 hours of initiation of anticoagulation was 70.51% (95% CI = 59.58 - 
79.52) and low clinical probability patients was 18.87% (95% CI 12.48 - 27.43).  
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DVT prevalence increased for each increasing value of modified Wells score.  When the 
modified Wells score was -2 the prevalence was 0.00% compared to a prevalence of 100% at 
a modified Wells score of 6.  The prevalence of DVT for each value of the modified Wells 
score is summarised below (see Figure 7): 
 
 
 
Figure 7  Graph demonstrating prevalence of DVT for each value of the modified Wells score.  Higher values of the 
modified Wells score are associated with higher frequencies of DVT.  The blue bars indicate patients with low clinical 
probability and the red bars indicate patients with high clinical probability. 
 
 
A Receiver Operated Characteristic (ROC) curve for the modified Wells score was calculated 
to investigate the relationship between test sensitivity and specificity.  The cut-off value of 
<2 as ‘low clinical probability’ and >=2 for ‘high clinical probability’ is shown below (see 
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Figure 8).  Please note that this is included just for illustrative purposes and is not equivalent 
to the statistically optimum cut off value. 
 
 
Figure 8  ROC curve for modified Wells score performance in patients on no anticoagulation treatment or evaluated 
within 48 hours of initiation of anticoagulation treatment.  The sensitivity and specificity for a cut-off value of 2 is shown 
(-------).  Please note that this is not equivalent to the statistically optimum cut off value. 
 
4.6 INPATIENTS VS OUTPATIENTS 
Of the 184 patients on no anticoagulation treatment or evaluated within 48 hours of 
initiation of anticoagulation treatment, 51 were outpatients and 133 were inpatients.  14 
(27.5%) of the outpatients had a DVT and 61 (45.9%) of the inpatients had a DVT.  The 
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performance of the Wells score in the inpatient and outpatient subgroups are summarised 
below (see Tables 13 & 14): 
 
 
Table 13 Modified Wells score performance parameters for all inpatients on no anticoagulation treatment or evaluated 
within 48 hours of initiation of anticoagulation treatment 
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 73.77% (61.56, 83.16)   
Specificity 79.17% (68.43, 86.95)   
Positive Predictive Value 75% (62.77, 84.22)   
Negative Predictive Value 78.08% (67.32, 86.03)   
Diagnostic Accuracy 76.69% (68.82, 83.07)   
   
 
   
 
 
 
 
 
 
Table 14 Modified Wells score performance parameters for all outpatients on no anticoagulation treatment or evaluated 
within 48 hours of initiation of anticoagulation treatment 
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 71.43% (45.35, 88.28)   
Specificity 78.38% (62.8, 88.61)   
Positive Predictive Value 55.56% (33.72, 75.44)   
Negative Predictive Value 87.88% (72.67, 95.18)   
Diagnostic Accuracy 76.47% (63.24, 86)   
   
 
   
 
The performance of the test between in and outpatient groups was not different. 
4.7 EFFECT OF HIV 
Of the 188 patients with recorded HIV results, 92 (48.9%) were positive and 96 (51.1%) were 
negative.  The DVT prevalence in HIV positive patients was 60.87% and in HIV negative 
patients 31.25%.   30 of the 46  patients (65.2%) on ARV’s had DVT compared to 25 of the 46 
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patients (54.3%) who were not on ARV’s.  There was not a statistically significant association 
between the DVT rate between the patients on ARV’s and those not on ARV’s (p = 0.2985). 
 
 
The performance of the modified Wells Score in HIV negative and positive patients is 
summarised below (see Tables 15 & 16) (Patients evaluated after 48hrs of initiation of 
anticoagulation treatment are not included).: 
 
 
Table 15 Modified Wells score performance parameters for all HIV negative patients on no anticoagulation treatment or 
evaluated within 48 hours of initiation of anticoagulation treatment 
 DVT PRESENT DVT ABSENT TOTAL 
HIGH CLINICAL 
PROBABILITY 
21 14 35 
LOW CLINICAL 
PROBABILITY 
2 42 45 
 24 56 80 
 
 
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 87.5% (69, 95.66)   
Specificity 73.68% (61.02, 83.35)   
Positive Predictive Value 58.33% (42.2, 72.86)   
Negative Predictive Value 93.33% (82.14, 97.71)   
Diagnostic Accuracy 77.78% (67.58, 85.46)   
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Table 16 Modified Wells score performance parameters for all HIV positive patients on no anticoagulation treatment or 
evaluated within 48 hours of initiation of anticoagulation treatment 
 DVT PRESENT DVT ABSENT TOTAL 
HIGH CLINICAL 
PROBABILITY 
29 5 34 
LOW CLINICAL 
PROBABILITY 
13 24 37 
 42 29 71 
 
 
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 69.05% (53.97, 80.93) 
Specificity 82.76% (65.45, 92.4) 
Positive Predictive Value 85.29% (69.87, 93.55) 
Negative Predictive Value 64.86% (48.76, 78.17) 
Diagnostic Accuracy 74.65% (63.45, 83.32) 
   
 
   
 
The negative predictive value of the modified Wells score in HIV negative patients was 
significantly greater than in HIV positive patients.  Otherwise, no performance parameter 
was significantly different between HIV positive and negative groups.   
 
It was hypothesised that because HIV positivity is an independent risk factor for the 
presence of DVT in the studied population, the addition of HIV to the modified Wells score 
would be likely to result in a more accurate score.  The modified Wells score was then 
calculated including HIV positivity as an additional score of 1.  This new score was now out 
of 10 and the cut off for the high clinical probability group was > or equal to 3 and the low 
clinical probability group was <3.  The performance of this score including the presence of 
HIV is summarised below (see Table 17): 
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Table 17  Performance parameters of modified Wells score including HIV as an additional score of 1 for all patients on no 
anticoagulation treatment or evaluated within 48 hours of anticoagulation using cut off of >=3 for high clinical 
probability and <3 for low clinical probability  
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 71.21% (59.36, 80.73) 
Specificity 89.41% (81.09, 94.33) 
Positive Predictive Value 83.93% (72.19, 91.31) 
Negative Predictive Value 80% (70.86, 86.81) 
Diagnostic Accuracy 81.46% (74.51, 86.85) 
   
 
   
 
A receiver operator characteristic curve for this new score was generated with the cut-off 
used indicated (Figure 9).  Please note that this is included for illustrative purposes and is 
not equivalent to the statistically optimum cut off value. 
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Figure 9 ROC curve for modified Wells score performance in patients on no anticoagulation treatement or evaluated 
within 48 hours of anticoagulation.  The sensitivity and specificity for the new cut-off value of 3 is shown (point A).  
Please note that this is not equivalent to the statistically optimum cut off value. 
 
 
This was compared to the original modified Wells score.  The ROC curve plots show that for 
the new test specificity was improved with a small decrease in sensitivity (see Figure 10): 
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Figure 10 Comparison of ROC curves for modified Wells score performance including (red curve) and not including (green 
curve) HIV as a criterion in patients on no antigoagulation treatement or evaluated within 48 hours of anticoagulation.  
The sensitivity and specificity for the cut-off values are shown (points A and B ).  The ROC curve plots show that for the 
new test specificity was improved with a small decrease in sensitivity 
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4.8 PERFORMANCE OF D-DIMER 
The overall sensitivity of the D-dimer test was 96.36% (95% CI = 87.68% to 99%) and 
specificity 29.09% (95% CI = 18.77% to 42.14%).  The diagnostic performance of the D-dimer 
test is summarised below (see Table 18) (Patients evaluated after 48hrs of initiation of 
anticoagulation treatment are not included): 
 
Table 18 D-dimer performance parameters for all patients on no anticoagulation treatment or evaluated within 48 hours 
of initiation of anticoagulation treatment 
 DVT PRESENT DVT ABSENT TOTAL 
D-DIMER POSITIVE 53 39 92 
D-DIMER NEGATIVE 2 16 18 
 55 55 110 
 
     
      
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 96.36% (87.68, 99)   
Specificity 29.09% (18.77, 42.14)   
Positive Predictive Value 57.61% (47.41, 67.2)   
Negative Predictive Value 88.89% (67.2, 96.9)   
Diagnostic Accuracy 62.73% (53.41, 71.19)   
 
The performance of the D-dimer in the low clinical probability Wells score group of patients 
is summarised below (see Table 19) (Patients evaluated after 48hrs of initiation of 
anticoagulation treatment are not included): 
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Table 19 D-dimer performance parameters for low clinical probability patients on no anticoagulation treatment or 
evaluated within 48 hours of initiation of anticoagulation treatment 
 DVT PRESENT DVT ABSENT TOTAL 
D-DIMER POS 13 32 45 
D-DIMER NEG 0 11 11 
 13 43 56 
 
 
 
   
Parameter  
Estimate  Lower - Upper 95% CIs 
 
 
 Sensitivity 100% (77.19, 100 )  
Specificity 25.58% (14.93, 40.24)  
Positive Predictive Value 28.89% (17.73, 43.37 )  
Negative Predictive Value 100% (74.12, 100)  
Diagnostic Accuracy 42.86% (30.77, 55.86)  
 
It should be noted that the sensitivity and negative predictive value of the D-dimer test in 
the group of patients with low clinical probability Wells scores were both 100%.   
4.9 PERFORMANCE OF COMBINED APPROACH 
The diagnostic performance of a combination of the modified Wells score and the D-dimer 
blood test for patients that had the D-dimer blood result is summarised below (see Table 
20) (Patients evaluated after 48hrs of initiation of anticoagulation treatment are not 
included): 
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Table 20 Combined Wells score and D-dimer performance parameters for all patients on no antigoagulation treatment 
or evaluated within 48 hours of initiation of anticoagulation treatment 
 DVT PRESENT DVT ABSENT TOTAL 
HIGH CLINICAL PROBABILITY and/or 
D-DIMER POSITIVE 
55 44 99 
LOW CLINICAL PROBABILITY and D-DIMER 
NEGATIVE 
0 11 11 
 55 55 110 
 
 
    
      
Parameter 
 
Estimate Lower - Upper 95% CIs 
 
 
 Sensitivity 100% (93.47, 100)   
Specificity 20% (11.55, 32.37)   
Positive Predictive Value 55.56% (45.74, 64.95)   
Negative Predictive Value 100% (74.12, 100)   
Diagnostic Accuracy 60% (50.66, 68.67)   
 
Of particular note is that no false negative results were obtained resulting in a test 
sensitivity and negative predictive value of 100%.   
 
 
4.10 SUMMARY 
The age of the patients with DVT was significantly lower than the patients without DVT.  
Significantly more inpatients had DVT’s in comparison to outpatients.  Similarly, significantly 
more HIV positive patients had DVT’s in comparison to HIV negative patients.   
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There was moderate agreement between the modified Wells score and VDU (the reference 
standard test) as determined by the Cohen Kappa test.  The McNemar test showed no 
significant difference between the tests. 
 
The modified Wells score was found to be significantly less accurate in patients evaluated 
after 48 hours of anticoagulation treatment.  Diagnostic accuracy of the modified Wells 
score was very similar between the inpatient and outpatient groups although the number of 
patients included in the outpatient group was small.  Diagnostic accuracy was not 
significantly different in HIV negative and HIV positive patient groups.  However the 
modified Wells score in HIV negative patients has a significantly higher negative predictive 
value. 
 
The D-dimer blood test had good sensitivity but poor specificity.  HIV positivity was an 
independent risk factor for the presence of a DVT.  Using HIV positivity as an additional 
criterion to the modified Wells score thus can result in improved diagnostic accuracy (due to 
improved specificity at the cost of a slight reduction in sensitivity). 
 
 
The performance of the Wells score combined with the D-dimer assay had very high 
sensitivity with no false negative results. 
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5 DISCUSSION  
5.1 DISCUSSION OF FINDINGS 
Patients with DVT’s were significantly more likely to be HIV positive and were significantly 
younger.  This was thought to be due to the higher rate of HIV positivity amongst young 
people generally in our population.  In the South African population, the HIV prevalence is 
highest in those ages 25-29 with a significant drop-off with increasing age.44  Similarly, the 
significantly increased rate of DVT amongst inpatients was thought to be explained by the 
higher rates of HIV positivity in this group.   
 
The diagnostic performance of the modified Wells score in patients evaluated after 48 hours 
of anticoagulation was significantly worse.  This was mainly due to an increased false 
negative rate resulting in a decreased sensitivity.  This is expected since the clinical signs in 
patients on prolonged anticoagulation therapy will resolve, resulting in a lower modified 
Wells score. 
 
The modified Wells score performed reasonably well as a screening test.  There was 
moderate agreement between the tests as determined by the Cohen Kappa test (as per 
Landis and Koch magnitude guidelines) and the McNemar test showed no significant 
difference between the tests.  Although this study supports the conclusion that the modified 
Wells score could never be used as a stand-alone test to exclude DVT given its negative 
predictive value of only 81%, its performance was comparable to that obtained by other 
studies.  More importantly is its performance when combined with a the D-dimer test which 
has a very high negative predictive value. 
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The modified Wells score performance was very similar between in- and outpatients.  The 
group of inpatients had slightly higher sensitivity, specificity and positive predictive value 
and a lower negative predictive value than the outpatients but none of these differences 
were statistically significant.  The overall accuracy of the test between inpatients and 
outpatients was very similar.  The results are somewhat surprising as inpatients are 
expected to have more co-morbid illnesses and have a higher pretest probability of DVT 
which should decrease specificity of the score.  The finding is likely to be due to the limited 
sample size, especially given the small group of outpatients included.     
 
The modified Wells score was slightly less accurate in HIV positive patients as compared to 
HIV negative patients.  This was mainly due to a lower negative predictive value.  This 
reduction is possibly due to the reduced inflammatory response that is present in these 
patients.  The sensitivity of the modified Wells score in HIV negative patients was also 
greater than in HIV positive patients.  This difference did not reach statistical significance.  
Despite this, the findings do suggest that the Wells score is accurate enough to be valid in a 
population with a high HIV seroprevalence.  Addition of HIV as one of the modified Wells 
score criteria improved test specificity and accuracy and should be considered when making 
use of the test in a high HIV seroprevalence setting.   
 
Overall, the D-dimer blood test showed a high sensitivity but a low specificity.  This low 
specificity is expected since D-dimer specificity is expected to be lower in populations with a 
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high prevalence of comorbid illnesses such as that of this study population which included a 
high percentage of inpatients and HIV positive patients.   
 
The combined test had an excellent sensitivity and negative predictive value and no patient  
who had received no anticoagulation treatment or who had been evaluated within 48 hours 
of initiation of anticoagulation treatment with a negative combined test was found to have 
a DVT.  Although this group of patients was small, the finding suggests that this approach is 
useful in assisting to exclude a DVT in our population.   The small size of this group also 
highlights the underutilisation of the D-dimer test in our setting.  Overall only 147 of the 230 
(63.9%) patients included in the study had D-dimer results available.  More importantly, 
considering that the D-dimer has been previously found to be most useful in outpatients, 
only 23 of the 57 (40.4%) of the outpatients in this study had D-dimer blood test performed.   
The small size of this group also may have an impact on the cost-effectiveness of this 
approach.  Whether this is truly a cost-effective approach in both in- and outpatients is a 
topic for future studies.  
5.2 STUDY LIMITATIONS 
5.2.1 Inadequate statistical power / small sample size 
The patients included in the study represented only a small proportion of the total VDUs 
performed in the three departments during the data collection period. A conservative 
estimate of the total number of VDUs performed is 50 per week.  This means an estimated 
800 patients were done during the study period and thus the study population represents 
approximately 25% or less of total VDU studies performed.  The small number of patients 
enrolled as a proportion of total VDUs may be due to several factors.  Firstly, the study was 
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based on voluntary participation of the referring doctor and did not work with a consecutive 
sample.  Secondly, anticoagulation for longer than 48 hours was an initial exclusion 
criterion.  Data on these patients was not collected until two months into the study, thus 
resulting in a smaller sample for this group of patients.   Finally, because of limited access to 
emergency ultrasound for deep vein thrombosis (for example, over weekends), a significant 
number of potential participants were placed on therapy before referral for ultrasound.    
 
Analysis of the different subgroups also suffers from a lack of statistical power due to a 
number of patients who had no D-dimer or HIV result available as well as the small number 
of outpatients included in the study.  This reflects the local practice since currently a 
relatively low number of patients have D-dimer assays prior to VDU.   Although this test is 
readily available in the local setting, there are no protocols promoting its use.   
 
A number of patients who had been on anticoagulation treatment for more than 48 hours 
were included in the study.  This was mainly to confirm the hypothesis that the modified 
Wells score would be less accurate in this group of patients since their clinical signs may 
have resolved.  Once this group was excluded from the statistical analysis, only 184 patients 
remained in the study.   
 
It is possible that ARV medications may influence the risks of DVT in HIV positive patients.  In 
the study there was a trend for more DVTs in patients on ARVs however this association was 
not statistically significant.  Had the sample size been larger, the difference in DVT rates 
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between the groups could have reached statistical significance.  This could be an interesting 
issue to examine in further studies with greater sample sizes. 
 
5.2.2 Bias  
There was a somewhat higher proportion of patients who were positive for DVT in the study 
than expected as compared to the results of previous studies.  Wells has a quoted 
prevalence of 15%.8  An informal pilot retrospective record review was conducted prior to 
commencement of formal data collection indicated prevalence of 35% amongst all patients 
coming for VDU.  This is somewhat lower than the prevalence of DVT in the formal study of 
41.7%.  This is probably due to an increased likelihood of clinicians including patients for 
whom they have a high clinical suspicion for DVT.   
 
Although other studies6, 8, 34 validating the modified Wells score and D-dimer test were 
conducted almost exclusively on low-risk outpatients, this study included both in- and 
outpatients.  There was, in fact, a bias toward including predominantly inpatients.  This is 
because inpatients were more likely to have positive studies and in the event of forms being 
incompletely filled in during the day or not included by the staff in sonar, it was only 
inpatients who could be found and their information obtained.  Forms of outpatients with 
incomplete data had to be discarded. 
 
Patients are more likely to have D-dimer blood tests already taken if they are inpatients.  
This could have resulted in more false positives since the D-dimer test is known to be non-
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specific and inpatients are more likely to have positive D-dimer tests due to other conditions 
such as systemic inflammation, liver disease etc. 
 
5.2.3 Not blinded 
Because the study information form was completed before VDU was performed, the 
information reflected on the form such as D-dimer level and modified Wells score result was 
not hidden from the operator performing the sonar.  This could possibly have led to bias in 
interpretation of the VDU.  Conversely, in the cases where the study information form was 
completed after the VDU was performed, the doctor assessing the modified Wells score was 
not blinded to the result of the VDU.  Again, the potential for bias exists. 
 
5.2.4 Limited comparability to previous studies 
In order to enable ease of comparison, the study was designed to be as similar as possible to 
previous studies which have investigated the validity of the modified Wells score.8  
Unfortunately due to logistical reasons and limited resources available, this study did differ 
in several respects from previous studies.   
 
Ideally, the study should have been confined to outpatients.  However, both in- and 
outpatients were included in this study.    The major reason for this was that in all three 
departments, far fewer outpatients are referred for VDU than inpatients.  Outpatients were 
also more difficult to enrol in the study.  If only outpatients had been included then the 
sample size would have been far smaller.   Nevertheless, there were advantages obtained 
from the inclusion of both in- and outpatients since this did allow for assessment of 
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modified Wells score and D-dimer test performance in inpatients in our local context and 
did allow for a comparison between in- and outpatients. 
 
In addition, the study included patients who were assessed more than 48 hours after 
initiation of anticoagulation therapy.  The reason for this was that it seemed to be of value 
to examine modified Wells score and D-dimer test performance in patients referred for VDU 
after being on therapy for more than 48 hours, since this is a relatively common occurrence 
in our setting due to the limited availability of emergency sonar for this indication. 
 
 
5.2.5 Use of VDU as a reference standard test 
Contrast venography is generally considered to be the reference standard for DVT.  In 
comparison to venography, VDU has a good sensitivity for proximal DVT but a lower 
sensitivity for calf vein thrombi.  The accuracy of VDU is also considered to be dependent on 
the operator.  In this study, operators were often inexperienced radiology registrars.   The 
VDU protocol used in the study was not standardised and many operators may only have 
examined the venous segments above the knee.  Details of the VDU report were not 
recorded on the data collection sheet.  These would include whether a proximal or distal 
DVT were present and the level of confidence of the findings of the report.  Both these 
variables would have affected the accuracy of the result and thus would have usefully been 
included.  
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In several other studies examining the Wells score, these limitations were addressed either 
by confirming the finding with venography3 or by conducting a follow-up VDU in 1-2 weeks8, 
although in general these are not cost effective strategies in clinical practice.1  Neither of 
these strategies were utilised in this study since performing additional venograms and 
calling patients back for additional VDU studies were not logistically feasible.  This may have 
resulted in some false positive or negative results.  Nevertheless, the yield of positive finding 
for repeat sonography in other studies is only 0-2%,1 which would not have made a 
significant difference to the results in this study.  Repeat sonography and venography are 
also not commonly utilised diagnostic strategies in routine practice in the local setting. 
 
5.2.6 Non standardisation of technique of Wells score assessment 
The modified Wells score was assessed by a range of clinicians with variable levels of clinical 
experience of DVT as well as variable levels of familiarity with the modified Wells score.  No 
training in application of the modified Wells score was provided.  Although, because of this, 
the process was not standardised, it does represent conditions similar to those in which the 
Wells score would be utilised in clinical practice. 
 
5.2.7 Non standardisation of definition of HIV result 
Because no blood tests were taken as part of the study (due to logistical constraints), in 
most cases the HIV status of the patients included in the study was determined based on 
blood testing taken previously.  If no recent blood result was available then the HIV status 
that the patient reported verbally was used.   It was left to the discretion of the clinician as 
to what constituted a recent negative test and whether they considered the verbal report of 
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HIV status as reliable.  In questionable cases they were advised to record the status as 
unknown.    Thus the HIV status recorded was subject to inaccuracies related to unreliability 
of patients verbal reporting of their status.  This is anticipated to result in some 
underreporting of positive status.  Patients may also have been recorded as being HIV 
negative based on a previous test but may have subsequently contracted HIV, resulting in 
misclassification of this group of patients.  
 
5.2.8 Non-generalisable results 
No control group was included in the study.  As a result, the findings may not be 
generalisable to other settings.   
 
 
5.3 RESULTS IN COMPARISON TO PREVIOUS STUDIES 
5.3.1 Demographics 
This study suggests that the population with DVT is significantly younger locally compared to 
previous studies conducted internationally.  The mean age of 44.8 years in this study is 
younger than any study included in Goodacre’s meta-analysis, in which mean ages ranges 
from 45 to 68 years with a median of 60 years.1  The mean age of patients with DVT was 
even younger (39.7 years).  This may be considered to be due to the high number of young 
HIV positive patients present in our hospital system.  In the current study the mean age of 
the HIV positive group was 36.0 years compared to the HIV negative group which was 49.8 
years. 
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5.3.2 Wells score 
A notable aspect of previous studies examining diagnostic performance of the Wells score is 
the heterogeneity of results.  The following ROC plot (modified from the meta-analysis by 
Goodacre, 2006)1 shows the variability in the results of Wells score performance and 
includes the result of the current study (see Figure 11): 
 
 
Figure 11  ROC plot (modified from Goodacre, 2006) shows the variability in the results of Wells score performance 
included in the meta-analysis compared to the result of the current study which is indicated with an “X” 
Note:  The studies included in the meta-analysis are different as they used the original Wells score which stratified 
patients into high / intermediate / low categories.  This study used the dichotomous form of the score which explains 
the intermediate sensitivity and specificity demonstrated in the ROC plot. 
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It is important to emphasise that the current study contained mainly inpatients.    Only two 
large studies have examined the performance of the Wells score in inpatients.  Both showed 
similar performance of the Wells score to this study.  In the study by Wells et al, the Wells 
score showed a prevalence of DVT of 76% / 19.7% / 10.0% in the high, intermediate and low 
probability groups.3  In the study by Constans et al the prevalence of DVT was 51% / 19% / 
9% in the high, intermediate and low probability groups.30  The current study showed a 
prevalence of DVT of 70.5% / 18.9% in the high and low probability groups, respectively.  In 
both studies the overall prevalence of DVT was lower (24.2% and 28.0% respectively) than in 
this study (41.7%). 
 
5.3.3 D-dimer 
Previous studies examining the diagnostic performance of the D-dimer assay show variable 
results due to differences in the assay used and the criteria for inclusion in the study.  The 
following ROC plot (modified from Goodacre, 2006) shows the variability in the results of D-
dimer assays included in the meta-analysis by Goodacre (this table is for latex tests only) 
and includes the results from the current study (See Figure 12): 
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Figure 12 ROC plot (modified from Goodacre, 2006) shows the variability in the results of D-dimer performance included 
in the meta-analysis compared to the result of the current study which is indicated with an “X” 
 
Data from the meta-analysis by Goodacre show pooled sensitivity of 94% and specificity of 
45% for all included studies.  Data from my study shows a similar sensitivity but a much 
lower specificity.  The lower specificity is not surprising as the study population contained 
mostly inpatients, who are more likely to have raised D-dimer levels for other reasons 
including HIV infection. 
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5.4 CONTRIBUTION OF THE STUDY AND PROPOSED FURTHER RESEARCH 
Despite methodological limitations, the results of the study suggest that the modified Wells 
score is a robust and practical tool for the investigation of suspected DVT in the local setting.  
During the study, modified Wells score assessments and VDUs were conducted in many 
ways under similar conditions to how these would be performed in everyday clinical practise 
in our setting.  For example, most modified Wells score assessments were completed by 
junior doctors and VDUs by radiology registrars or sonographers.   
 
No patients with a negative combined test were found to have DVT which is in keeping with 
the results of previous studies and suggests that combining these tests may be useful to 
exclude the presence of a DVT.    This study may not be seen to be sufficiently large to base 
recommendations that VDU is unnecessary for patients with low clinical probability Wells 
scores and negative D-dimers and further studies should be undertaken to investigate this 
group of patients.   A potential significant contribution to current practice may be to 
consider a negative combined test as a reasonable basis for withholding potentially harmful 
therapy until the condition can be definitively excluded by VDU. 
 
A particularly important finding of this study is that the D-dimer assay may be underutilised 
in local practice.    Overall only 147 of the 230 (63.9%) patients included in the study had D-
dimer results available.  More importantly, considering that the D-dimer has been 
previously found to be most useful in outpatients, only 23 of the 57 (40.4%) of the 
outpatients in this study had D-dimer blood test performed. 
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The study found no DVT in 11 patients with low pre-test probability scores and a negative D-
dimer; however, 50 patients with negative modified Wells scores did not have D-dimers 
taken.  It is in this group of patients that a finding of a negative D-dimer may have made a 
venous Doppler unnecessary had it been taken. 
 
Based on the study findings, a diagnostic algorithm including the modified Wells score and 
D-dimer assay should be further investigated for local use.  An example of such an algorithm 
is that suggested by Wells (See Figure 13): 
 
 
Figure 13  An example of a diagnostic algorithm (as per Wells, 2003) that may be used as a basis for future research 
 
Future studies should determine the safety, accuracy and cost-effectiveness of the proposed 
approach in the local setting.  Such studies could examine the utility of a repeat VDU in 
patients with initially negative VDU in order to confirm the accuracy of the initial VDU in our 
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practice.  It is currently uncertain what the true accuracy is in local practice and whether a 
repeat VDU in clinically high risk patients, especially if the D-dimer test is positive, may not 
also be useful.  This study did not record data on the patient’s CD4 counts or the details of 
the antiretroviral therapy that the patients were receiving.   The association of CD4 count 
and ARV therapy with DVT risk could be looked at in future studies with larger sample sizes. 
 
Future studies should also attempt to address some of the methodological limitations 
present in this study.   Requiring that a D-dimer be taken prior to inclusion in the study will 
increase the group of patients with negative combined tests in order to give a more 
accurate idea of the true negative predictive value of this combined approach in this group 
of patients.   
 
5.5 SUMMARY 
Despite several methodological limitations including inadequate statistical power, bias, lack 
of blinding, non-standardisation of VDU technique and potential inaccuracies in reporting of 
HIV status, the results of this study are consistent with the findings of previous studies and 
may support the validity of the modified Wells score and D-dimer assay in a South African 
population with a high HIV seroprevalence.  Due to the abovementioned methodological 
limitations, further research is needed.  Making use of a new score which uses HIV positivity 
as an additional criterion to the Wells score may result in improved diagnostic accuracy. 
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The more widespread utilisation of the modified Wells score, especially in conjunction with 
D-dimer assay as part of a diagnostic algorithm will make investigation of this condition 
simpler and more cost effective.  A diagnostic algorithm previously proven to be cost 
effective is suggested for adoption in local clinical practice as well as a basis for future 
research.    Future research could examine the effect of CD4 count and ARV drugs on the risk 
for DVT as well as investigating the most cost-effective approach for DVT investigation in 
South Africa. 
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6 CONCLUSION 
The results of this study confirm the validity of the modified Wells score in a local South 
African population with a high HIV seroprevalence.  The widespread adoption of such a 
score will help to stratify patients risk for DVT and is especially of value for clinicians 
inexperienced in assessing patients with DVT.   
 
The score was found to be significantly less accurate in patients evaluated after 48 hours of 
anticoagulation treatment.  As expected, this was mainly due to a reduction in test 
sensitivity.  Further data analysis in this study thus excluded this group of patients.  
Diagnostic accuracy of the modified Wells score was very similar between the inpatient and 
outpatient groups, although the number of patients included in the outpatient group was 
small.   
 
This is the first study to validate the modified Wells score in a high HIV seroprevalence 
setting and is the first to examine the effect of HIV on test accuracy.  Diagnostic accuracy 
was found to be slightly better in HIV negative than in HIV positive patients although this 
difference was not statistically significant.  HIV positivity was an independent risk factor for 
the presence of a DVT.  Using HIV positivity as an additional criterion to the modified Wells 
score can thus result in improved diagnostic accuracy (due to improved specificity at the 
cost of a slight reduction in sensitivity). 
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The D-dimer blood test performed as expected with good sensitivity but poor specificity.  As 
previous studies have shown the main clinical utility of the D-dimer test is that a negative 
test essentially excludes the presence of DVT in low risk patients.  In this study also, the 
combination of modified Wells score and D-dimer blood testing identified all patients with 
DVT if this approach was applied only to patients evaluated within 48 hours.  The only two 
false negatives were present in the group of patients evaluated after 48 hours.  Of note was 
the large number of patients, especially outpatients, with low clinical probability modified 
Wells scores who did not have D-dimer results available, suggesting that the D-dimer is 
underutilised in the group of patients that would benefit most from its use. 
 
This study should be seen as a basis for future research.  Specifically, the accuracy and 
viability of utilisation of a diagnostic algorithm using the modified Wells score and D-dimer 
assay should be investigated since this strategy may have the potential to significantly 
reduce costs which is highly desirable in our setting. 
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7 APPENDICES 
 
1 Informed consent form 
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2 Data collection sheet 
 
   
73 
 
  
74 
 
3 Letter to the Department Heads 
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